Growth hormone
IGF-1 LR3
A modified IGF-1 analogue used in animal research, with studies showing that altered signaling does not reliably produce growth or preserve cognition.
Controlled fetal-sheep and mouse studies; important negative growth and cognition findings
Also known as: Long arginine 3 IGF-1 · LR3-IGF-1
Practical use
Evidence interpretation and clinical context
- Keep the model attached
- Fetal sheep and male disease-model mice are not adult human trials.
- Report the intended outcome
- Plaque changes should sit beside the negative memory result.
- Distinguish activity from benefit
- A nutrient or tissue response does not necessarily improve growth or function.
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
Overview
Long arginine 3 IGF-1, commonly called LR3, has altered interactions with IGF-binding proteins. It is a distinct research molecule whose results cannot be substituted for native IGF-1 or another IGF medicine.
Risks and limitations
Animal growth and brain studies do not establish long-term human metabolic or proliferative safety. A change in nutrient utilization can occur without the intended benefit, as illustrated by reduced amino acids without improved fetal growth.
How to read this
Different endpoints can disagree within the same study. Plaque appearance, body composition, memory and growth should each be reported on their own terms.
Research explained
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
Who was studied
Growth-restricted fetal sheep, with seven animals per group studied over one week.
What was found
LR3 did not improve fetal body weight, circulating insulin or glucose-stimulated insulin secretion versus control. Circulating amino acids decreased.
What it cannot establish
Placental-insufficiency physiology and fetal exposure differ greatly from adult human use. The study does not support a general anabolic benefit.
Read the original studyIntranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.
Who was studied
Male Alzheimer-model and wild-type mice followed during seven months of experimental treatment.
What was found
Some amyloid-plaque and body-composition measures changed, but behavioral and memory outcomes were not preserved.
What it cannot establish
This was a male mouse model, not a human dementia trial. Tissue changes cannot be described as prevention of cognitive decline.
Read the original studyClinical status in the reviewed evidence
These publications establish research use in animals. They do not establish a licensed LR3 treatment or a demonstrated human performance or neuroprotective benefit.
Supporting sourceTarget engagement can coexist with failure
The fetal-sheep amino-acid change and mouse plaque findings show biological activity, while the intended growth or cognitive outcomes remained unimproved.
Supporting sourceClaims versus findings
Not supported
IGF signaling guarantees useful growth and better cognition.
The cited experiments found no fetal-growth improvement and no preservation of mouse behavioral or memory outcomes.
Check the evidenceCommon questions
Can an IGF-1 medicine’s evidence be applied directly to LR3?
No. LR3 is a modified analogue; the cited studies must be evaluated as evidence for that specific molecule.
SourceSources
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
Sources checked 2026-10-01.
General education; not a personal treatment plan.